Introduction In roughly a decade, artificial intelligence (AI) has moved from initial development for natural images toward broader deployment in clinical practice.1 The United States (US) Food and Drug Administration’s (FDA) list of authorized AI- and machine-learning-enabled devices grew from only 7 entries before 2010 to 343 by mid-2021, still heavily concentrated in radiology (70.3%) and cardiovascular (12.0%) specialties but no longer limited to them.2 Market reports indicate a high...
